View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 14, 2019

Orchestra BioMed licenses Virtue SEB to Terumo

Orchestra BioMed has entered a deal providing exclusive worldwide development and commercialisation rights for its Virtue Sirolimus-Eluting Balloon (SEB) to Japanese medical devices maker Terumo.

Orchestra BioMed has entered a deal providing exclusive worldwide development and commercialisation rights for its Virtue Sirolimus-Eluting Balloon (SEB) to Japanese medical devices maker Terumo.

Designed for percutaneous coronary and peripheral interventions, the Virtue SEB is a non-coated drug-eluting angioplasty balloon delivering a bioabsorbable, sustained-release formulation of sirolimus.

Sirolimus is intended for the prevention of restenosis after a percutaneous interventional procedure.

The SEB obtained breakthrough device designation from the US Food and Drug Administration (FDA) in April for coronary in-stent restenosis (ISR).

Terumo expects the device to boost its Intervention Systems division, which comprises advanced coronary and peripheral endovascular treatment solutions.

Orchestra BioMed chairman and CEO David Hochman said: “Terumo has a proven global distribution and operations infrastructure with the sales and marketing expertise necessary to make Virtue SEB broadly accessible to physicians and patients worldwide, pending regulatory approvals.”

As part of the licensing agreement, Orchestra BioMed will receive a one-time upfront payment of $30m, along with a $5m equity investment. Terumo will also pay clinical and regulatory milestones in the future.

Terumo has committed to work with Orchestra BioMed to finance and execute a global clinical programme for obtaining regulatory approval for Virtue SEB in various markets and indications, including ISR, small coronary vessels and peripheral artery disease below-the-knee.

Orchestra BioMed intends to conduct a registrational trial for ISR under an Investigational Device Exemption (IDE) from the FDA within the next year.

Furthermore, Orchestra BioMed will receive royalties and per unit payments for the exclusive use of its sustained-release sirolimus formulation used in the device.

The company retains the rights to develop and license Virtue SE’s technology for clinical applications in areas other than coronary and peripheral vascular interventions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU